GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Shiller PE Ratio

BetterLife Pharma (XCNQ:BETR) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BetterLife Pharma Shiller PE Ratio Historical Data

The historical data trend for BetterLife Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Shiller PE Ratio Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BetterLife Pharma Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BetterLife Pharma's Shiller PE Ratio

For the Biotechnology subindustry, BetterLife Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Shiller PE Ratio falls into.



BetterLife Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BetterLife Pharma's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, BetterLife Pharma's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.01/125.0724*125.0724
=-0.010

Current CPI (Jan. 2024) = 125.0724.

BetterLife Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 0.100 98.920 0.126
201407 -0.031 99.315 -0.039
201410 -0.145 99.473 -0.182
201501 -1.170 98.209 -1.490
201504 -0.240 99.710 -0.301
201507 -0.390 100.579 -0.485
201510 -0.001 100.500 -0.001
201601 -1.163 100.184 -1.452
201604 -0.502 101.370 -0.619
201607 -0.261 101.844 -0.321
201610 -0.134 102.002 -0.164
201701 -0.109 102.318 -0.133
201704 -0.058 103.029 -0.070
201707 -0.001 103.029 -0.001
201710 0.128 103.424 0.155
201801 -0.040 104.056 -0.048
201804 -0.300 105.320 -0.356
201807 -0.200 106.110 -0.236
201810 -0.400 105.952 -0.472
201901 -0.130 105.557 -0.154
201904 -0.190 107.453 -0.221
201907 -0.280 108.243 -0.324
201910 -0.150 107.927 -0.174
202001 -0.680 108.085 -0.787
202004 0.004 107.216 0.005
202007 -0.090 108.401 -0.104
202010 -0.250 108.638 -0.288
202101 -0.535 109.192 -0.613
202104 -0.040 110.851 -0.045
202107 -0.050 112.431 -0.056
202110 -0.030 113.695 -0.033
202201 -0.050 114.801 -0.054
202204 -0.040 118.357 -0.042
202207 -0.010 120.964 -0.010
202210 -0.050 121.517 -0.051
202301 0.000 121.596 0.000
202304 -0.010 123.571 -0.010
202307 -0.010 124.914 -0.010
202310 -0.002 125.310 -0.002
202401 -0.010 125.072 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BetterLife Pharma  (XCNQ:BETR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BetterLife Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma (XCNQ:BETR) Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Ahmad Doroudian Director, Senior Officer